$28.52
4.20% today
Nasdaq, Apr 03, 06:49 pm CET
ISIN
US05370A1088
Symbol
RNA
Sector
Industry

Avidity Biosciences Inc Target price 2025 - Analyst rating & recommendation

Avidity Biosciences Inc Classifications & Recommendation:

Buy
100%

Avidity Biosciences Inc Price Target

Target Price $67.07
Price $29.77
Potential
Number of Estimates 14
14 Analysts have issued a price target Avidity Biosciences Inc 2026 . The average Avidity Biosciences Inc target price is $67.07. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 14 analysts: 14 Analysts recommend Avidity Biosciences Inc to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Avidity Biosciences Inc stock has an average upside potential 2026 of . Most analysts recommend the Avidity Biosciences Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 10.90 7.65
14.02% 29.85%
EBITDA Margin -3,451.01% -6,689.74%
41.29% 93.85%
Net Margin -3,178.73% -6,115.23%
12.90% 92.38%

12 Analysts have issued a sales forecast Avidity Biosciences Inc 2025 . The average Avidity Biosciences Inc sales estimate is

$7.6m
Unlock
. This is
29.85% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$21.0m 92.66%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $10.9m 14.02%
2025
$7.6m 29.85%
Unlock
2026
$17.0m 122.34%
Unlock
2027
$271m 1,495.95%
Unlock
2028
$844m 211.25%
Unlock
2029
$1.4b 63.35%
Unlock

3 Analysts have issued an Avidity Biosciences Inc EBITDA forecast 2025. The average Avidity Biosciences Inc EBITDA estimate is

$-511m
Unlock
. This is
35.98% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-487m 29.38%
Unlock
, the lowest is
$-539m 43.38%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-376m 61.10%
2025
$-511m 35.98%
Unlock
2026
$-599m 17.11%
Unlock
2027
$-411m 31.40%
Unlock

EBITDA Margin

2024 -3,451.01% 41.29%
2025
-6,689.74% 93.85%
Unlock
2026
-3,523.65% 47.33%
Unlock
2027
-151.46% 95.70%
Unlock

5 Avidity Biosciences Inc Analysts have issued a net profit forecast 2025. The average Avidity Biosciences Inc net profit estimate is

$-468m
Unlock
. This is
34.48% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-385m 10.69%
Unlock
, the lowest is
$-598m 72.07%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-346m 0.69%
2025
$-468m 34.95%
Unlock
2026
$-524m 12.05%
Unlock
2027
$-376m 28.26%
Unlock
2028
$-350m 6.86%
Unlock

Net Margin

2024 -3,178.73% 12.90%
2025
-6,115.23% 92.38%
Unlock
2026
-3,081.80% 49.60%
Unlock
2027
-138.53% 95.50%
Unlock
2028
-41.46% 70.07%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -2.89 -3.90
0.69% 34.95%
P/E negative
EV/Sales 272.56

5 Analysts have issued a Avidity Biosciences Inc forecast for earnings per share. The average Avidity Biosciences Inc EPS is

$-3.90
Unlock
. This is
34.48% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-3.21 10.69%
Unlock
, the lowest is
$-4.99 72.07%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-2.89 0.69%
2025
$-3.90 34.95%
Unlock
2026
$-4.37 12.05%
Unlock
2027
$-3.14 28.15%
Unlock
2028
$-2.92 7.01%
Unlock

P/E ratio

Current -10.27 16.84%
2025
-7.63 25.71%
Unlock
2026
-6.81 10.75%
Unlock
2027
-9.50 39.50%
Unlock
2028
-10.20 7.37%
Unlock

Based on analysts' sales estimates for 2025, the Avidity Biosciences Inc stock is valued at an EV/Sales of

272.56
Unlock
and an P/S ratio of
468.05
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 191.19 26.15%
2025
272.56 42.56%
Unlock
2026
122.59 55.02%
Unlock
2027
7.68 93.73%
Unlock
2028
2.47 67.87%
Unlock
2029
1.51 38.78%
Unlock

P/S ratio

Current 328.32 54.28%
2025
468.05 42.56%
Unlock
2026
210.51 55.02%
Unlock
2027
13.19 93.73%
Unlock
2028
4.24 67.87%
Unlock
2029
2.59 38.78%
Unlock

Current Avidity Biosciences Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Mar 18 2025
Needham
Locked
Locked
Locked Mar 17 2025
Chardan Capital
Locked
Locked
Locked Mar 17 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 17 2025
Citigroup
Locked
Locked
Locked Mar 13 2025
BMO Capital
Locked
Locked
Locked Mar 12 2025
B of A Securities
Locked
Locked
Locked Mar 10 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 18 2025
Locked
Needham:
Locked
Locked
Mar 17 2025
Locked
Chardan Capital:
Locked
Locked
Mar 17 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 17 2025
Locked
Citigroup:
Locked
Locked
Mar 13 2025
Locked
BMO Capital:
Locked
Locked
Mar 12 2025
Locked
B of A Securities:
Locked
Locked
Mar 10 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today